Valproic acid (VPA) is a well-established therapeutic used in treatment of seizure and mood disorders as well as migraines and a known hepatotoxicant. About 50% of VPA users experience metabolic disruptions, including weight gain, hyperlipidemia, and hyperinsulinemia, among others. Several of these metabolic abnormalities are similar to the effects of circadian rhythm disruption. In the current study, we examine the effect of VPA exposure on the expression of core circadian transcription factors that drive the circadian clock via a transcriptiontranslation feedback loop. In cells with an unsynchronized clock, VPA simultaneously upregulated the expression of genes encoding core circadian transcription factors that regulate the positive and negative limbs of the feedback loop. Using low dose glucocorticoid, we synchronized cultured fibroblast cells to a circadian oscillatory pattern. Whether VPA was added at the time of synchronization or 12 h later at CT12, we found that VPA disrupted the oscillatory expression of multiple genes encoding essential transcription factors that regulate circadian rhythm. Therefore, we conclude that VPA has a potent effect on the circadian rhythm transcriptiontranslation feedback loop that may be linked to negative VPA side effects in humans. Furthermore, our study suggests potential chronopharmacology implications of VPA usage.
Introduction
Most organisms operate on a roughly 24-hour light/dark cycle, known as circadian rhythm. The regulation of circadian rhythm involves a tightly-controlled hierarchy system orchestrating rhythmicity in the brain and peripheral tissues (Farnell et al., 2011; Albrecht, 2012) . Both clinical and animal studies have established that disruption of circadian rhythm is associated with a variety of pathological states that include perturbations of metabolism, immune function, sleep, and fertility, among others (Sen and Sellix, 2016; Castanon-Cervantes et al., 2010; McHill and Wright Jr., 2017; Morikawa et al., 2005; Karlsson et al., 2001) . Circadian misalignment with environmental rhythms can arise from modern-day lifestyles that involve long-distance jet travel, exposure to nighttime light, erratic meal schedules, and shift work. In addition, xenobiotics, including environmental toxicants (JimenezOrtega et al., 2012; Garrett and Gasiewicz, 2006; Xu et al., 2010) and drugs (Li and Levi, 2007; Li et al., 2002; Johansson et al., 2011; Koyanagi and Ohdo, 2002; Iurisci et al., 2009; Terazono et al., 2008; Ortiz-Tudela et al., 2014; Osland et al., 2011) , have been shown to cause disruptions to circadian rhythm. A recent study showed that > 50% of all drugs approved for clinical use target genes or proteins that show rhythmic expression in mice (Zhang et al., 2014) . As human exposure to xenobiotics continues to increase, it is imperative to develop a comprehensive understanding of their impact on circadian rhythms as well as how circadian rhythm affects their metabolism, potency, and toxicity.
Mammalian circadian timing is driven by the master clock, located in the suprachiasmatic nucleus (SCN) of the hypothalamus, which generates signals to synchronize peripheral clocks in other tissues [reviewed in (Albrecht, 2012) ]. These tissues express autoregulatory clock proteins that generate circadian rhythmicity by transcription-translation negative feedback loops (Shearman et al., 2000) . Core components of these feedback loops include Clock and Bmal1, members of the positive limb, and negative limb members Period1, Period2, Period3 (Per1, Per2 and Per3), Cryptochrome1 and Cryptochrome2 (Cry1 and Cry2), and Rev.-erbα and β. Clock and Bmal1 heterodimerize and activate transcription by binding to E box sequences in target gene promoters, including those of genes encoding the negative limb components. Per and Cry proteins accumulate and physically interact with the Clock/Bmal1 heterodimer at E boxes to block activated transcription (Shearman et al., 2000; Zheng et al., 1999; Kume et al., 1999) . In addition, Rev.-erbs (α, β) and RORs (α, β, γ) control the cyclic expression of the Bmal1 gene, with RORs inducing expression and Rev.-erbs suppressing it (Partch et al., 2014; Sato et al., 2004; Preitner et al., 2002) . The outcome of this process is the oscillatory expression and subsequent activity of the circadian rhythm transcription factors in both the brain and peripheral tissues . A study to comprehensively catalog circadian gene expression in mice showed that this regulatory loop has been found to confer rhythmic expression on about 43% of all genes in at least one tissue type (Zhang et al., 2014) .
The equilibrium between lysine acetyltransferases (KATs, also known as histone acetyltransferases or HATs) and lysine deacetylases (KDACs, also known as histone deacetylases or HDACs) is hypothesized to be critical for proper circadian gene expression. The Clock/Bmal1 heterodimer recruits the KATs, p300/CBP, to facilitate transactivation at target genes (Takahata et al., 2000) . In addition, association of KDACs and their complexes with clock-regulated gene promoters has been shown to exhibit a rhythmic periodicity (Duong et al., 2011; Feng et al., 2011; Kim et al., 2014) . Accordingly, rhythmic histone acetylation has been observed at promoters of several core clock components, including Per1, Per2, and Cry1 (Etchegaray et al., 2003) . In the case of the Per1 gene, increased histone acetylation at its promoter has been shown to activate transcription (Naruse et al., 2004) . Clock itself has intrinsic KAT activity that targets its binding partner, Bmal1, in a rhythmic fashion. Bmal1 acetylation leads to the recruitment of Cry1 and subsequent gene repression (Hirayama et al., 2007; Doi et al., 2006) . Sirt1, a Class III, NAD + -dependent KDAC, is required for highmagnitude circadian expression of several core clock genes and has been shown to balance the KAT activity of Clock (Nakahata et al., 2008; Asher et al., 2008) . Zinc-dependent Class I KDACs also contribute to circadian clock physiology. The KDAC1/2-containing Sin3 and Nucleosome Remodeling and Deacetylase (NuRD) complexes associate with promoters of Per and Cry genes in rhythmic fashion to repress their transcription (Kim et al., 2014; Naruse et al., 2004; Duong and Weitz, 2014) . Finally, Rev.-erbα (encoded by the Nr1d1 gene) has been found to recruit the NCoR/KDAC3 complex to repress Bmal1 transcription (Yin and Lazar, 2005) . In mouse liver, oscillatory association of Rev.-erbα and KDAC3 with genes that regulate lipid metabolism contributes to hepatic lipid homeostasis (Feng et al., 2011) . Thus, reversible acetylation at histones and non-histone proteins controlled by KATs and KDACs is an integral part of the circadian transcription-translation feedback loop.
Valproic acid (VPA) is a carboxylate derivative of valeric acid prescribed over 7 million times per year as of 2014 (http://clincalc.com/ DrugStats/Top200Drugs.aspx; https://www.ahrq.gov/research/data/ meps/index.html). It causes both acute and chronic, reversible hepatotoxicity [reviewed in (Cotariu and Zaidman, 1988; Nanau and Neuman, 2013; Chang and Abbott, 2006) ]. After two decades of clinical use, VPA was reported to be a KDAC inhibitor (KDACi) (Gottlicher et al., 2001) . VPA has been shown to cause metabolic side effects in about 50% of regular users, including non-alcoholic fatty liver disease, hyperinsulinemia, hyperlipidemia, and weight gain that leads to increased body mass index, among others (Luef et al., 2009; Perucca, 2002) . Disruption of circadian rhythm is also linked to several metabolic abnormalities, including cardiovascular disease and metabolic syndrome with characteristics of hyperlipidemia, hepatic steatosis, reduced insulin sensitivity, and obesity [reviewed in (Eckel-Mahan and Sassone-Corsi, 2013; Froy, 2011) ]. The similarities in side effects between chronic VPA usage and circadian rhythm disruption and the emerging roles of KATs and KDACs in regulating circadian transcription feedback loops, raise the possibility that VPA may disrupt clock function. A previous study showed that oscillatory activity of an integrated PER2 promoter driving expression of the luciferase gene (PER2::LUC) was phase-shifted by VPA treatment in tissue explants of mouse SCN and in cultured human fibroblasts (Johansson et al., 2011) . In the current study we investigated whether VPA exposure impacts the expression of genes encoding multiple core circadian transcription factors (TFs) in a cell culture model system. In cells that were not synchronized to the circadian clock, we showed that treatment with VPA or another clinically-relevant KDACi, vorinostat, simultaneously increased the expression of genes encoding circadian TFs that regulate the positive and negative limbs of the circadian clock. In cells synchronized to the circadian clock, we found that VPA exposure disrupts the oscillatory expression pattern of genes encoding TFs regulating both limbs of the circadian transcription-translation feedback loop. These results suggest that the common side effects of VPA could be mediated in part through disruptions to circadian rhythm.
Materials and methods

Cell lines, reagents, and antibodies
Murine hepatoma cells (Hepa-1c1c7) and murine fibroblast cells (NIH/3T3) were obtained from American Type Culture Collection and maintained in Minimum Essential Media α (MEMα) and Dulbecco's Modified Eagle Medium (Invitrogen), respectively, containing 10% fetal bovine serum (FBS) (Peak Serum) and 0.1% gentamicin (Invitrogen). Dexamethasone (Dex) and valproic acid (VPA) were obtained from Sigma-Aldrich. Anti-acetylated histone H3 (06-599), H3K27ac (07-360), and acetylated histone H4 (06-866) were all obtained from Millipore. Anti-histone H3 (Clone D1H2) was obtained from Cell Signaling. The secondary goat anti-rabbit antibody (111-035-144) was purchased from Jackson Immunoresearch.
RNA analysis
Hepa-1c1c7 or NIH/3T3 cells were seeded in 6 well dishes at 2.5 × 10 5 cells per well. After 24 h, cells were treated with VPA (5 mM)
for 5 h or 24 h followed by lysis in Trizol (Invitrogen). Total RNA was isolated according to the manufacturer's protocol using the Nucleospin RNA II kit (Clontech) and included DNase I digestion. cDNA was generated using the qScript cDNA synthesis kit (Quanta). qPCR was performed using a StepOne Plus instrument (Applied Biosystems) with SYBR Green mastermix (Quanta) according to the manufacturer's specifications. Table 1 lists the gene-specific exon-exon and exon-intron primer pairs used to measure levels of mRNA and nascent transcripts, Table 1 PCR Primers used in the study.
Gene
Forward primer Reverse primer Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 respectively. In each experiment the test gene Ct values were normalized against the geometric mean of the corresponding glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and hypoxanthine guanine phosphoribosyltransferase (Hprt) Ct values to obtain ΔCt values for each sample. These housekeeping genes were chosen for normalization based on our long-term observations that their expression is not affected in these cell lines by treatment with Dex and/or various KDAC inhibitors.
To determine changes in expression between treated and untreated samples, the ΔCt vales for treated samples were normalized against those from the untreated controls for each test gene to derive ΔΔCt values. In each experiment, average primer efficiency was calculated from standard curves and used to convert the ΔΔCt values into fold change. The fold change values were then used to graph results and calculate SEM. The ΔCt values of untreated samples were compared to treated samples using the paired t-test (Graphpad Prism) to determine whether the changes were statistically significant (p ≤ 0.05).
Western blot analysis
Whole cell lysates were prepared by adding 2× SDS-PAGE buffer to cells. After denaturation proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad) at 400 mA for 4 h. Membranes were blocked with 2% non-fat dry milk in TBS for 1 h, followed by exposure to primary antibodies at 4°C overnight. After subsequent exposure to secondary antibodies, membranes were washed 3 times with TBS/0.1% Tween-20 solution. The proteins were visualized with enhanced chemiluminescence (ECL) solution using a chemiluminescence imaging system (BioRad).
Per1 sensitivity studies
NIH/3T3 cells were seeded in 6 well dishes at 2.5 × 10 5 cells per well. After 24 h, cells were treated with Dex (0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μM) for 1 h. Cells were harvested and RNA was isolated and analyzed as described above. The fold change values were fit with a Dose Response curve using Graphpad Prism. Again, a paired t-test was run to determine whether there were significant differences between untreated and Dex treated samples.
Circadian rhythm synchronization
NIH/3T3 cells were seeded in 60 × 15 mm dishes at 3 × 10 5 cells per dish. After 3 days of incubation, media was changed to media supplemented with media containing charcoal stripped FBS (1% FBS). After 24 h, cells were treated with Dex (1 nM) for 1 h. After treatment, the media was removed and the cells were washed with 1% FBS supplemented media before being replaced with fresh media (1% FBS), which marks the 0 h time point (circadian time 0 or CT0). The cells were then harvested at various time points over the next 48 h and RNA was isolated and analyzed as described above. In experiments that included VPA treatment, VPA (5 mM) was added at the same time as Dex treatment or at Circadian Time 12 (CT12). In the former case, when VPA was added at the same time as Dex, it was re-added with fresh media (1% FBS) after cells were washed to remove Dex. After RT-qPCR (described above) fold change values were derived based on comparison of treated conditions with the untreated condition (at the time of Dex treatment). The fold change values were fit with the following equation using Graphpad Prism:
Using this equation the following parameters were extrapolated from each gene: 1) baseline, a measurement of the average expression level around which the curve oscillate over time and 2) amplitude, the change in expression at high and low points relative to the corresponding baseline. The ΔCt values of two different treatments (e.g. untreated vs. Dex alone or Dex treatment vs. Dex and VPA cotreatment) were compared using the paired t-test to determine whether the changes were statistically significant (p ≤ 0.05). C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 3. Results
Valproic acid and vorinostat induce expression of genes encoding circadian rhythm TFs
During the analysis of expression profiling data in multiple cell lines, we noted that KDAC inhibitors (KDACi), including VPA, induced mRNA levels of several transcription factors (TFs) that regulate the circadian clock (not shown). One of the cell lines we examined, Hepa1c1c7, was derived from mouse hepatoma. Since VPA is established to impact liver function (Cotariu and Zaidman, 1988; Nanau and Neuman, 2013; Chang and Abbott, 2006) , we used this cell line to verify the impact of VPA on mRNA levels of several TFs vital to the negative (Per1, Per2, Cry1, Cry2, Nr1d1 [Rev-erbα]) and positive (Bmal1) limbs of the circadian transcription-translation feedback loop. Fig. 1A shows that all circadian genes tested are significantly upregulated by 5 h VPA treatment when compared to untreated cells. To determine whether this represents a transient response to the drug, we measured expression of these genes after 24 h of VPA treatment. With the exception of Nr1d1, all of the genes tested demonstrate sustained upregulation in the presence of VPA.
To determine whether this was a cell-specific response to VPA treatment, we repeated the experiment in NIH/3T3 cells, a standard in the field for examining the circadian rhythm transcription-translation feedback loop in vitro (Farnell et al., 2011; Nagoshi et al., 2005) . In these cells, neither short-nor long-term VPA exposure affected expression of Per1 and Per2 and expression of Nr1d1 was mildly but significantly decreased. However, as was the case in the Hepa1-c1c7 cells, expression of Cry1, Cry2, and Bmal1 were significantly upregulated by 5 h VPA treatment (Fig. 1B) . At 24 h VPA treatment, upregulated expression of Cry1 and Cry2 was sustained. While VPA impacted expression of more circadian TF genes in Hepa-1c1c7 cells, it caused significant and simultaneous upregulation of genes encoding TFs in the negative (Cry1 and Cry2) and positive (Bmal1) limbs of the circadian transcriptional feedback loop.
Since VPA is known to have targets other than Class I KDACs (Terbach and Williams, 2009), we also exposed both cell lines to vorinostat, another clinically-relevant KDACi. Vorinostat, a hydroxamate, and VPA, a simple aliphatic acid, are structurally distinct and likely to have different off-target effects. At 5 h treatment in Hepa-1c1c7 cells (Fig. 1C) , vorinostat caused significant upregulation of 4 of 6 circadian TF genes tested, including three members of the negative limb (Per2, Cry1, Cry2) and Bmal1, representing the positive limb. Thus, there is strong overlap in the circadian TF genes upregulated by VPA and vorinostat at 5 h, which captures mostly primary changes in gene expression due to drug treatment. At 24 h of vorinostat treatment, 3 of the 4 genes upregulated at 5 h are still significantly higher than baseline although the magnitude of the difference is lower. In NIH/3T3 cells, vorinostat causes increased expression of the same three genes upregulated by VPA at 5 h (Fig. 1D ). Cry1 and Bmal1 were significantly upregulated; Cry2 expression was upregulated relative to control in each replicate but the changes fell just short of significance by the paired ttest (p = 0.07). By 24 h of vorinostat treatment, only Bmal1 upregulation is sustained. In general, at the 5 h treatment time, the effects of VPA and vorinostat are very similar in each cell line, suggesting that early upregulation of the genes encoding the circadian TFs is mediated through the shared target of VPA and vorinostat, Class I KDACs (Khan et al., 2008) . Effects of the two KDACi are more divergent at the 24 h time point, which will capture secondary effects of drug treatment.
Finally, to ensure that both VPA and vorinostat display KDAC-inhibiting activity at the concentrations used, we treated Hepa-1c1c7 (Fig. 1E ) and NIH/3T3 (Fig. 1F ) cells with each drug and assayed acetylation of histones H3 and H4 by Western blot with antibodies against histone H3 acetylated at K27 or at K9/K14 and a pan-acetylH4 antibody. The results show that VPA and vorinostat induce robust increases in both H3 and H4 acetylation at 5 and 24 h treatment.
Low dose glucocorticoid activated circadian rhythm expression of core peripheral clock factors
Because Bmal1 gene expression is normally antiphase to Per and Cry gene expression during the circadian cycle (Yagita et al., 2001 ) the above findings raise the possibility that VPA or vorinostat may disrupt the oscillatory expression of essential circadian genes important for proper clock function. Immortalized, non-transformed cell lines such as NIH/3T3 have been most commonly used to study clock function in Fig. 2 . Per1 is hypersensitive to glucocorticoid treatment in the presence or absence of VPA. (A) NIH/3T3 cells were treated for 1 h with increasing concentrations of Dex (0 nM, 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM or 1 μM). RNA was isolated and subjected to RT-qPCR with exon-intron primer sets to measure nascent transcripts. Fold changes in nascent transcripts for each treatment concentration relative to levels in untreated cells for Per1, Tgm2, Sgk1, and Ampd3. The half maximal effective concentration (EC 50 ) was calculated for each gene tested (shown in the inset). (B). NIH/3T3 cells were treated with Dex (1 nM) in the presence or absence of VPA (5 mM) for 1 h. The Dex was then removed by washing and the cells were exposed to serum-free media containing VPA for an additional hour. RNA was isolated and subjected to RT-qPCR. All graphs represent the results of 3-6 independent replicates. Error bars represent standard error of the mean (SEM). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Asterisks (*) represent significant changes between untreated cells and cells treated with Dex. C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 vitro (Nagoshi et al., 2005; Balsalobre et al., 2000 Balsalobre et al., , 1998 . Reddy et al. reported that low dose dexamethasone treatment synchronizes the circadian clock because the Per1 gene is hypersensitive to activation by glucocorticoids and triggers the oscillatory expression of other circadian TFs (Reddy et al., 2009) . To determine whether this works in NIH/ 3T3 cells, we characterized the Dex dose-response relationship for Per1 and several other glucocorticoid-activated genes and determined the EC 50 concentration for each gene. As shown in Fig. 2A , the EC 50 for Per1 is the lowest at 1 nM. At this concentration Per1 is activated while other glucocorticoid-sensitive genes are unaffected. We previously reported that VPA and other KDACi impair glucocorticoid receptor-activated transcription at up to 50% of target genes (Kadiyala et al., 2013) . Because Per1 activation is vital for the oscillation of other circadian genes, it was important to determine whether KDACi treatment disrupts this activation. NIH/3T3 cells were treated with 1 nM Dex for 1 h in order to activate the Per1 gene in the presence and absence of VPA, as shown in Fig. 2B . VPA treatment had no effect on the nascent transcript levels of Per1.
To determine whether low dose glucocorticoid and Per1 activation can initiate circadian rhythm, contact-inhibited NIH/3T3 cells were treated with 1 nM Dex for 1 h, after which the Dex-treated media was removed and replaced with low serum media (1% FBS) without Dex. The mRNAs encoding several core peripheral clock genes were monitored over 48 h along with two housekeeping genes (Gapdh and Hprt). Nonlinear regression was used to curve fit the data to a sine wave with circadian time 0 (CT0) set at the time of Dex removal. As expected, expression of the housekeeping genes does not oscillate (Fig. 3F) . In contrast, exposure to low dose Dex induces the oscillatory expression of genes encoding the core circadian TFs (Fig. 3A-E) . The Bmal1 gene, belonging to the positive limb, has an oscillatory pattern opposite to those of the Per2, Cry1, Cry2, and Nr1d1 genes, all of which belong to the negative limb. Within the first 8 h after Dex treatment expression of the latter genes increases, while Bmal1 mRNA levels significantly decrease. Bmal1 gene expression peaks between 8 and 16 h and between 32 and 40 h, times when the expression of genes encoding TFs of the negative limb are declining. Table 2 shows 1) baseline, a measurement of the average expression level around which the curve oscillates over time and 2) amplitude, the change in expression at high points (peaks) and low points (troughs) relative to the corresponding baseline. These values for each of the five circadian TF genes tested in cells synchronized with Dex alone are listed in column 2. The times at which peaks and troughs occurred for each gene over the 48 h period were also determined and are shown for Dexsynchronized cells in the unshaded columns of Tables 3 and 4.
Valproic acid affects circadian gene expression in a gene-selective fashion
To ascertain whether VPA alters circadian gene oscillation in vitro, we exposed Dex-synchronized NIH/3T3 cells to VPA. VPA was added to Fig. 3 . Low dose glucocorticoid activates circadian rhythm gene expression of core peripheral clock transcription factors. NIH/3T3 cells were treated with Dex (1 nM) for 1 h. The cells were then washed and the media was replaced with low-serum (1%) media (referred to as Circadian Time 0, CT0) and gene expression was followed for the next 48 h. RNA was isolated and subjected to RT-qPCR with primer sets to measure the oscillatory pattern of mRNA levels for circadian TF genes (A-E) as well as two housekeeping genes, Gapdh and Hprt (F). All graphs represent fold changes in expression at various time points relative to expression at the time of Dex addition and are the summary of 7-17 independent biological replicates. Error bars represent standard error of the mean (SEM). Asterisks (*) represent significant changes between expression in untreated cells and in cells treated with Dex. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Toxicology and Applied Pharmacology 339 (2018) 110-120 the NIH/3T3 cultures at the same time as Dex and was maintained in the medium after Dex washout. To determine whether VPA acts as a KDACi under these conditions, lysates were generated from NIH/3T3 cells just prior to Dex and VPA addition (UT) and at CT1, 8, 24, and 48. Fig. 4F shows that VPA induces a robust increase in histone H3 and H4 acetylation that is maintained through the 48 h treatment period. To determine whether VPA exposure impacts clock function, levels of mRNA from circadian TF genes were monitored and analyzed as described above. In Fig. 4A -E, the curves generated by Dex treatment alone (Fig. 3A-E ) are indicated by a dotted line in each graph for the purpose of comparison. Baselines and amplitudes were extrapolated from the curves for each gene and are listed in Table 2 (shaded columns). Changes in these parameters caused by VPA exposure provide a measure of whether it alters the range of expression for a given gene. The results show that the oscillatory expression of some, but not all, of the circadian TF genes were affected by VPA. Curve-fitting of Per2 mRNA expression (Fig. 4A) does not indicate any significant impact of VPA treatment on baseline or amplitude [ Table 2 , compare values in column 3 (VPA,Dex) to those in column 2 (Dex alone)]. For Nr1d1 mRNA (Fig. 4B) , the amplitude for the VPA-treated cells was similar to that observed in cells treated with Dex alone, but baseline expression was mildly but significantly decreased.
Expression of the Cry1 (Fig. 4C) and Cry2 (Fig. 4D ) genes were similarly affected by VPA exposure at CT0. While the amplitudes of their oscillatory expression cycles were not changed, their baseline expression was increased by 40% (Cry1) and 65% (Cry2) ( Table 2 , compare baselines for Dex alone and VPA, Dex). Thus VPA resets the range of their expression to a higher level. In support of this, fold changes in Cry1 and Cry2 mRNAs calculated in the presence of both VPA and Dex (relative to levels of mRNA at the time of initial treatment) were significantly higher than those observed with Dex treatment over much of the 48 h cycle (denoted with pound signs in Fig. 4C and D) . The cycle of Bmal1 mRNA expression (Fig. 4E ) was altered the most by VPA treatment. While the amplitude was unaffected by VPA exposure at CT0 (Table 2) , the baseline expression was significantly reduced by > 40%. Thus, in contrast to its effects on Cry1 and Cry2 expression, VPA resets the range of Bmal1 expression to lower level. In contrast to the negative limb circadian TF genes, VPA induced a 6 h phase shift in the oscillatory cycle of Bmal1 mRNA levels. In the presence of Dex alone, Bmal1 mRNA levels reached a low point (trough) within 2 h after Dex removal (Table 3 , column 4). However, the presence of VPA caused a prolonged decrease in Bmal1 mRNA that results in the trough being reached at C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 about 8 h after Dex removal (Table 3 , column 5). This 6 h phase delay is maintained over a second 24 h cycle as evidenced by a 6 h shift in the times of peaks and troughs for Bmal1 mRNA when comparing VPA, Dex to Dex alone (Table 3 , shaded vs. unshaded columns). These results show that VPA treatment at CT0 has a dramatic effect on the positive limb of the circadian cycle.
Addition of Valproic acid at CT12 causes phase shifts in expression of genes encoding TFs belonging to both limbs of the circadian transcriptiontranslation feedback loop
In the experiments described above, cells were exposed to VPA at a time when expression of the TF genes in the negative limb were increasing and Bmal1 gene expression was decreasing. It is possible that adding VPA 12 h later, when Bmal1 gene expression is on the rise, may have less of an effect on oscillatory expression cycles. To address this, we treated Dex-synchronized cells with VPA 12 h after Dex was washed out (Circadian Time 12, CT12) and monitored expression of the circadian TF genes. As in Fig. 4 , the graphs of Fig. 5 show the curves generated by Dex treatment alone (Fig. 3) as a dotted line. Relative to Dex alone, VPA treatment at CT12 had no effect on baseline expression of Bmal1 mRNA but significantly increased amplitude by > 2-fold (Table 2 , compare unshaded columns, CT12 VPA, Dex vs. Dex). It also caused an immediate, robust increase in Bmal1 mRNA levels before they trended downward after CT16 (Fig. 5E ). This produced a 3 h phase shift [ Table 4 , compare peak and trough times of VPA, Dex (shaded columns) with Dex alone]. Although the curve-fitting does not reflect it, there may also be a lengthening of the period between peaks of Bmal1 expression (Fig. 5E ). The first peak occurred at CT16 while the subsequent peak occurred around CT44, a difference of 28 h.
The effects of VPA exposure at CT12 on expression of circadian TF genes in the negative limb were more pronounced than the effects of exposure at CT0. As shown in Fig. 5A , the cycle of Per2 mRNA expression, which was unaffected by VPA exposure around CT0, showed significant decreases in baseline (20%) and amplitude (65%) ( Table 2) as well as a 5 h phase shift (Table 4 ). In the case of Nr1d1, (Fig. 5B) , VPA at CT12 did not affect baseline expression of the oscillatory cycle but significantly increased amplitude by > 2-fold (Table 2 ) and caused a 3-4 h phase shift (Table 4 ). The oscillatory expression Cry1 and Cry2 mRNAs (Figs. 5C-D) was profoundly impacted by VPA treatment at CT12. The cycle of Cry1 mRNA expression showed a significant increase in baseline expression (Table 2 , CT12 VPA, Dex vs Dex). In addition, there was a phase shift of 12 h (Table 4) resulting in an opposite oscillatory cycle relative to Dex treatment alone (Fig. 5C ). In fact, its oscillation pattern becomes similar, rather than opposite, to that of Bmal1 mRNA (compare solid lines in Fig. 5C and E). After VPA treatment at CT12, Cry2 mRNA essentially loses its oscillatory pattern of expression (Fig. 5D ) and, at most time points tested, its average level of expression is significantly higher relative to Dex alone, which is reflected in a significantly higher baseline (Table 2) . Fig. 4 . VPA exposure around CT0 affects expression of circadian transcription factor genes in a gene-selective manner. (A-E) NIH/3T3 cells were treated with Dex (1 nM) and VPA (5 mM). After 1 h, the cells were washed and the media was replaced with low-serum (1%) media (CT0). For the cells previously treated with VPA, VPA was re-added after Dex removal and maintained for the remainder of the experiment. RNA was isolated at 4 h intervals and subjected to RT-qPCR. All graphs represent fold changes in expression at various time points relative to expression at the time of Dex,VPA addition and are the summary of 3-6 independent biological replicates. Curve-fitting data from the cells exposed to VPA is indicated by the solid line. Curves derived from analysis of cells exposed to Dex alone (Fig. 3) C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 4. Discussion VPA, a well-established anticonvulsant and mood stabilizer, causes several metabolic disturbances similar to those observed by disruption of circadian rhythm. Two previous in vitro studies indicated that VPA or an additional KDACi, trichostatin A (TSA), affected the oscillatory expression of the Per1 (Naruse et al., 2004) and Per2 (Johansson et al., 2011) genes, which function in the negative limb of the circadian transcription-translation feedback loop. In the current study we show that exposure to the KDACi, VPA or vorinostat, alters expression of genes encoding multiple core circadian TFs in two murine cell lines of different tissue origin. Expression of the Cry1, Cry2, and Bmal1 genes were sensitive to short-term (5 h) treatment with VPA or vorinostat in both cell lines. The effects of these KDACi were more divergent after 24 h exposure. Although we cannot rule out off-target secondary effects, these differences could be due to the fact that VPA is a Class Iselective KDACi while vorinostat is a pan-KDACi which also efficiently inhibits the Class IIb KDAC6 (Bantscheff et al., 2011) . In cells synchronized to the circadian transcription-translation feedback loop through glucocorticoid treatment, VPA exposure perturbs oscillatory expression of genes encoding core circadian TFs that participate in both the positive and negative limbs of the circadian clock. VPA exposure impacts baseline, amplitude, and phase of oscillatory expression in a gene-dependent manner. Also, the effects of VPA exposure are different at the beginning of the circadian cycle (CT0) versus mid-cycle (CT12). These findings suggest that VPA has the potential to disrupt circadian rhythms at the organismal level and alter physiological homeostasis.
Glucocorticoid signaling is thought to be a component of the communication between the master clock in the SCN and the peripheral clocks. Serum glucocorticoid levels peak in the morning and reach a low point in the evening (Krieger et al., 1971; Weitzman et al., 1971) . We used low dose glucocorticoid to initiate the rhythmic expression of genes encoding five core circadian TFs through upregulation of the Per1 gene in NIH/3T3 cells. In addition to the genes shown in Figs. 3-5, Per1 mRNA was also monitored but, after the initial Dex-induced peak in expression, there were no further oscillations in its expression (data not shown), consistent with the findings of Osland et al. (Osland et al., 2011) . Clock mRNA was not examined because it does not oscillate during the circadian cycle in cultured fibroblasts (Osland et al., 2011; Yagita et al., 2001) In mouse liver Clock mRNA and protein show shallow oscillations (Ripperger and Schibler, 2006; Preitner et al., 2002) . Instead, Clock protein undergoes robust changes in post-translational modifications during the circadian cycle .
Our results in cells not synchronized to the circadian clock suggest that both VPA and vorinostat may disrupt the circadian transcriptional feedback cycle. However, the two drugs have very different pharmacokinetic properties and dosing schedules. In humans vorinostat is rapidly cleared from serum with a half-life of 1.5-2 h (Rubin et al., 2006) Fig. 5 . Addition of Valproic Acid at CT12 causes phase shifts in expression of genes encoding TFs belonging to both limbs of the circadian transcriptional feedback loop. NIH/ 3T3 cells were synchronized to a circadian cycle as described previously. At CT12 (12 h from when Dex removal), the cells were treated with VPA (5 mM). The cells were then harvested every 4 h until 48 h. All graphs represent fold changes in expression at various time points relative to expression at the time of Dex, VPA addition and are the summary of 4-7 independent biological replicates. Curvefitting data from the cells exposed to VPA is indicated by the solid line. Curves derived from analysis of cells treated with Dex alone (Fig. 3) C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 while VPA persists with a half-life in serum of 8-20 h (Perucca, 2002; Johannessen and Johannessen, 2003) . In addition, vorinostat, approved for use against advanced cutaneous T cell lymphoma, is typically given once daily while VPA is taken 1-3× daily. Its extended half-life combined with multiple daily dosing makes VPA a more likely candidate for disruption of the circadian clock because it probably persists in human serum over a 24 h cycle, especially if patients are taking multiple daily doses. VPA was initially added at the beginning of the circadian cycle to model VPA users who take a daily dose in the mornings when serum glucocorticoid levels are high. After Dex washout, it was maintained in the medium to model users taking multiple daily doses. In this case oscillatory expression of genes encoding TFs in both the positive and negative limbs of the circadian feedback loop were affected. Baseline expression of Cry1 and Cry2 genes was significantly increased while that of the Bmal1 gene was decreased. This could shift the balance of expression between circadian TFs towards those in the negative limb of the circadian cycle. In addition, the cycle of Bmal1 gene expression was phase delayed by 6 h, putting its oscillatory expression out of sync with expression of genes encoding TFs that drive the negative limb of the circadian cycle because their phases of expression were unaffected. We also measured VPA exposure at CT12, which would be analogous to a VPA user taking a dose in the evening. This had a stronger effect, causing multiple changes in the rhythmic cycling of TF genes in both negative and positive limbs of the circadian feedback loop. Similar to VPA exposure at CT0, baseline expression of the Cry1 and Cry2 genes was significantly increased. In addition, Cry1 gene expression was phase advanced by 12 h and Cry2 gene expression lost its rhythmicity. Both Cry1 and Cry2 have been implicated in maintaining period length and circadian rhythm, and their delicate balance of expression is crucial for proper circadian function (van der Horst et al., 1999) .
While unaffected by VPA exposure at CT0, baseline expression of the Per2 gene was significantly reduced and its expression was phasedelayed by approximately 5 h when VPA exposure occurred at CT12. This finding agrees with that of Johansson et al., who demonstrated that the magnitude of VPA-induced phase-shifts in circadian Per2 promoter activity was dependent on the time of VPA exposure (Johansson et al., 2011) . In the case of Bmal1 gene expression, its amplitude was increased by about 50% and its phase was delayed by 3 h. Since the phase of Nr1d1 gene expression was similarly delayed, the oscillatory expression of these two genes remains opposite. However, due to the large phase advance of Cry1 gene expression, VPA exposure at CT12 caused expression of the Bmal1 and Cry1 genes to peak at almost the same time rather than Bmal1 being antiphase to Cry1 in the presence of Dex alone (Table 4) . The large Cry1phase shift also puts it out of the normal sync with Per2 gene expression, which peaks about 3 h before Cry1 in the presence of Dex alone (Table 4 ).
The differences in response of the circadian TF genes to VPA exposure at CT0 and CT12 are likely a reflection of the transcription complexes present at their promoters at those times. For example, at CT0 in the presence of Dex alone, Bmal1 expression was trending downward, possibly due to the inhibitory action of Rev.-erbα proteins at its promoter. VPA exposure causes a prolonged downward trend in Bmal1 gene expression under these circumstances. However, at CT12 Bmal1 expression is on an upward cycle, possibly due to ROR proteins at its promoter. VPA exposure at this time causes a large increase in Bmal1 expression. The exact mechanisms behind these differences are unclear but deserve further study.
While VPA has several mechanisms of action (Terbach and Williams, 2009) , its effects on transcription may be due, at least in part, to its ability to inhibit KDACs and thereby alter the acetylation state of both histones and transcriptional regulatory proteins (Scholz et al., 2015) . Our comparison of VPA and vorinostat showed that both induced histone acetylation (Fig. 1E, F) in unsynchronized Hepa-1c1c7 and NIH/3T3 cells. In addition, expression of TF genes in both the positive and negative limbs of the circadian feedback loop was induced by VPA or vorinostat (Fig. 1A-D) . We also showed that VPA treatment induces robust increases in histone acetylation over the 48 h treatment period in clock-synchronized NIH/3T3 cells. The study of Johansson et al. found that VPA and a second KDACi, TSA, had very similar effects on rhythmic PER2::LUC gene expression in SCN tissue explants and cultured primary fibroblasts (Johansson et al., 2011) . The hydroxamic acids, vorinostat and TSA, have very different structures compared to VPA, a simple aliphatic acid, and are likely to have distinct off-target effects. Thus, their similar effects on circadian TF gene expression in this study and on PER2::LUC expression in the Johansson study (Johansson et al., 2011) suggest that they are mediated through their shared targets, the zinc-dependent KDACs. In further support of this, Johansson et al. tested the effects of inhibitors of various pathways that VPA has been shown to modulate (e.g. MAPK, JNK, GABA signaling) (Terbach and Williams, 2009 ) and found that they did not block any of the effects of VPA on the amplitude and phase of PER2::LUC expression in cultured human fibroblasts (Johansson et al., 2011) .
Altered amplitudes and phase shifts of circadian TF expression have been documented in various disease states and in aging. Decreased rhythm amplitudes have been found in patients suffering from depression as well as from bipolar disorder (Yang et al., 2009; Souetre et al., 1989) . Older rodents have also been shown to have reduced circadian rhythm amplitudes compared to younger rodents (Kolker et al., 2003) . In fact, systems with robust circadian amplitudes are more resistant to phase perturbation than those with lower amplitudes (Pittendrigh et al., 1991) . Therefore, the reduction of circadian amplitude may cause instability of circadian rhythm and other homeostatic processes (Tao et al., 2015; Monk, 2005) . Familial advanced sleep phase syndrome is a circadian disruption disorder where patients experience early sleep onset and delayed awakening (Toh et al., 2001) . Phase advances are also implicated in the process of aging, as well as decreased tolerance to abrupt phase shift changes (Monk, 2005) . Due to modern-day lifestyles, many people experience possible phase shifts on a daily basis. In fact, certain stimuli, including light, cause phase shifts through increased Per levels that subsequently reset the phases of other genes in the feedback loop (Kolker et al., 2003) . Based on our study and that of Johansson, VPA is a phase-setting agent, causing shifts when added at various points of the circadian cycle (Johansson et al., 2011) . Our study clearly shows that VPA exposure mid-cycle, at CT12, caused major phase shifts for all core clock components. However, even when added at CT0, VPA causes a major phase delay in oscillatory Bmal1 gene expression and a significant decline in baseline expression. Deletion of a single clock gene rarely causes complete loss of rhythmicity (Zheng et al., 2001; van der Horst et al., 1999) with the exception of Bmal1; knockout of Bmal1 in mice severely disrupts circadian rhythm with a complete loss of rhythmicity in constant darkness as well as locomotor impairment (Bunger et al., 2000) . Thus, disruptions in circadian Bmal1 expression alone may lead to robust downstream physiological effects.
VPA has been in clinical use for almost 40 years for a number of disease states including seizure, mood disorders, and migraines. With a half-life in humans of 8-20 h, patients taking multiple daily doses likely maintain some serum level of VPA throughout a 24 h period (Perucca, 2002) . Our study shows that VPA exposure has profound effects on negative and positive limbs of the circadian transcriptional feedback loop in vitro. The approval of 4 KDACi for clinical use against cancer in the last decade has spurred evaluation these drugs for use in other diseases (Haberland et al., 2009) ; thus, human exposure to these drugs is likely to increase. In light of this, the circadian impact of clinically relevant KDAC inhibitors, such as VPA, is worthy of further study. A recent study cataloged genes that showed oscillatory expression in a variety of tissues in mice (Zhang et al., 2014) . Among these genes were those encoding the targets of over 50% of all drugs approved for clinical use. To reduce toxicities associated with xenobiotic exposure, it is essential to understand how therapeutics such as VPA impact circadian rhythm and to determine when, during the 24 h cycle, they could be C.A. Griggs et al. Toxicology and Applied Pharmacology 339 (2018) 110-120 given with minimal negative circadian effects.
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